Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists

被引：17
|
作者：
Mann, Johannes F. E. [1 ,2 ]
Muskiet, Marcel H. A. [3 ]
机构：
[1] KfH Kidney Ctr, 15 Isoldenst, D-80804 Munich, Germany
[2] Friedrich Alexander Univ, Univ Hosp, Dept Nephrol & Hypertens, Erlangen, Germany
[3] Vrije Univ, Amsterdam Univ, Med Ctr, Dept Internal Med,Diabet Ctr, Amsterdam, Netherlands
来源：
KIDNEY INTERNATIONAL | 2021年 / 99卷 / 02期
关键词：
RENAL OUTCOMES; CARDIOVASCULAR OUTCOMES; LIRAGLUTIDE;
D O I：
10.1016/j.kint.2020.08.036
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：314 / 318
页数：5
相关论文
共 50 条
  • [41] Evaluation of Drug Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors Based on Target Molecular Binding Occupancy
    Takayanagi, Risa
    Uchida, Takumi
    Kimura, Koji
    Yamada, Yasuhiko
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2018, 41 (02) : 153 - 157
  • [42] The role of GLP-1 in type 2 diabetes (T2D): effects of DPP-4 inhibition and GLP-1 receptor blockade
    Aulinger, B. A.
    de Heer, J.
    Bedorf, A.
    Kutscherauer, G.
    Goeke, B.
    Schirra, J.
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2014, 122 (03)
  • [43] SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study
    Fu, Edouard L.
    Wexler, Deborah J.
    Cromer, Sara J.
    Bykov, Katsiaryna
    Paik, Julie M.
    Patorno, Elisabetta
    BMJ-BRITISH MEDICAL JOURNAL, 2024, 385
  • [44] Comparison between Clinical Efficacy of DPP-4 Inhibitors and GLP-1 Analogs in Type 2 Diabetics
    Faber-Heinemann, G.
    DIABETES STOFFWECHSEL UND HERZ, 2012, 21 (06): : 357 - 368
  • [45] Impact of Either GLP-1 Agonists or DPP-4 Inhibitors on Pathophysiology of Heart Failure
    Takahashi, Ayako
    Ihara, Madoka
    Yamazaki, Satoru
    Asanuma, Hiroshi
    Asakura, MaSarlori
    Kitakaze, Masafumi
    INTERNATIONAL HEART JOURNAL, 2015, 56 (04) : 372 - 376
  • [46] Therapeutic stimulation of GLP-1 and GIP protein with DPP-4 inhibitors for type-2 diabetes treatment
    Sharma A.
    Paliwal G.
    Upadhyay N.
    Tiwari A.
    Journal of Diabetes & Metabolic Disorders, 14 (1):
  • [47] Evaluating Second-Line Treatment Options for Type 2 Diabetes: Focus on Secondary Effects of GLP-1 Agonists and DPP-4 Inhibitors
    Boland, Cassie L.
    DeGeeter, Michelle
    Nuzum, Donald S.
    Tzefos, Maria
    ANNALS OF PHARMACOTHERAPY, 2013, 47 (04) : 490 - 505
  • [48] The risk of acute pancreatitis with GLP-1 receptor agonists and DPP-4 inhibitors: a retrospective observational cohort study
    Koro, C. E.
    Sowell, M. O.
    Stender, M.
    Chhabra, P.
    Allen, J. K.
    Krzywy, H. J.
    DIABETOLOGIA, 2013, 56 : S183 - S184
  • [49] Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice
    Enrico Longato
    Barbara Di Camillo
    Giovanni Sparacino
    Lara Tramontan
    Angelo Avogaro
    Gian Paolo Fadini
    Cardiovascular Diabetology, 19
  • [50] Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice
    Longato, Enrico
    Di Camillo, Barbara
    Sparacino, Giovanni
    Tramontan, Lara
    Avogaro, Angelo
    Fadini, Gian Paolo
    CARDIOVASCULAR DIABETOLOGY, 2020, 19 (01)
12345